• Artiva outlined second-half 2026 data disclosures for AlloNK with rituximab in its Phase 2a autoimmune basket trial.
• Updated readouts are expected, not yet presented, with follow-up from refractory rheumatoid arthritis, Sjögren disease, systemic sclerosis cohorts.
• The company plans to start a Phase 3 registrational trial in refractory rheumatoid arthritis, comparing AlloNK with rituximab against rituximab alone.
• Management framed earlier rheumatoid arthritis results as encouraging, citing favorable activity with no major safety signals reported to date.
• Topline Phase 3 results are targeted by end-2028, a key value inflection point for the program’s regulatory path.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artiva Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609080730PRIMZONEFULLFEED9822348) on September 08, 2026, and is solely responsible for the information contained therein.